CELON PHARMA S A

🇵🇱Poland

Country: 🇵🇱Poland

Ownership: Public

Established: 2002-01-01

Employees: 515

Market Cap: $412.8M

Website: http://www.celonpharma.com

Clinical Trials

Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis

Phase 2

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: CPL409116
Other: Placebo

First Posted Date: 2022-05-16

Last Posted Date: 2023-11-15

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 100

Registration Number: NCT05374785

Locations: 🇵🇱
Centrum Nowoczesnych Terapii Sp. z o.o. "Dobry Lekarz", Kraków, Poland
🇵🇱
Medyczne Centrum Hetmańska, Poznań, Poland
🇵🇱
Samodzielny Publiczny Zespół Opieki Zdrowotnej w Tomaszowie Lubelskim, Tomaszów Lubelski, Poland

and more 7 locations

Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia

Phase 2

Recruiting

Conditions: Parkinson Disease
Dyskinesia, Medication-Induced

Interventions: Drug: CPL500036 - high dose
Drug: CPL500036 - low dose
Drug: Placebo

First Posted Date: 2022-03-28

Last Posted Date: 2024-05-16

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 108

Registration Number: NCT05297201

Locations: 🇺🇦
"INET-09" LLC (Medical Center), Zaporizhzhia, Ukraine
🇵🇱
Instytut Zdrowia dr Boczarska-Jedynak Sp. Z o.o., Sp. K.,, Oświęcim, Małopolska, Poland
🇵🇱
Mazowiecki Szpital Bródnowski, Warszawa, Mazowieckie, Poland

and more 9 locations

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: CPL500036 - low dose
Drug: CPL500036 - high dose

First Posted Date: 2022-03-14

Last Posted Date: 2024-07-11

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 189

Registration Number: NCT05278156

Locations: 🇭🇺
Psychiatry Department of Tolna County Balassa Janos Hospital, Szekszárd, Hungary
🇺🇦
Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods., Kyiv, Ukraine
🇺🇦
Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",, Lviv, Ukraine

and more 13 locations

Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes

Phase 2

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: CPL207280
Drug: Placebo

First Posted Date: 2022-02-21

Last Posted Date: 2023-02-08

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 80

Registration Number: NCT05248776

Locations: 🇵🇱
BioResearch, Kajetany, Nadarzyn, Poland

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CPL409116
Drug: Placebo

First Posted Date: 2020-12-17

Last Posted Date: 2022-05-16

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 65

Registration Number: NCT04670757

Locations: 🇵🇱
BioResearch Group Sp. z o.o., Kajetany, Nadarzyn, Poland

Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CPL207280
Drug: Placebo
Drug: Metformin hydrochloride 750 mg

First Posted Date: 2020-11-09

Last Posted Date: 2021-08-18

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 68

Registration Number: NCT04622111

Locations: 🇵🇱
BioResearch Group Sp. z o.o., Kajetany, Nadarzyn, Poland

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Phase 1

Recruiting

Conditions: Cholangiocarcinoma
Endometrial Cancer
Gastric Cancer
Bladder Cancer
Squamous Non-small Cell Lung Cancer
Sarcoma
Other Solid Tumours

Interventions: Drug: CPL304110

First Posted Date: 2019-11-04

Last Posted Date: 2024-02-07

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 42

Registration Number: NCT04149691

Locations: 🇵🇱
BioResearch Group sp. z o.o., Nadarzyn, Poland
🇵🇱
Klinika Onkologii, Europejskie Centrum Zdrowia, Otwock, Poland
🇵🇱
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland

and more 4 locations

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Esketamine DPI - high dose
Drug: Placebo DPI
Drug: Esketamine DPI - medium dose
Drug: Esketamine DPI - low dose

First Posted Date: 2019-05-29

Last Posted Date: 2020-04-28

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 88

Registration Number: NCT03965858

Locations: 🇵🇱
Mazowieckie Specalistyczne Centrum Zdrowia, Pruszkow, Poland
🇵🇱
Uniwersytecki Szpital Kliniczny, Wroclaw, Poland
🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

and more 8 locations

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

Phase 2

Completed

Conditions: Bipolar Depression

Interventions: Drug: Esketamine DPI - high dose
Drug: Esketamine DPI - low dose
Drug: Placebo DPI
Drug: Esketamine DPI - medium dose

First Posted Date: 2019-05-29

Last Posted Date: 2021-03-19

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 88

Registration Number: NCT03965871

Locations: 🇵🇱
Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej, Choroszcz, Poland
🇵🇱
Uniwersytecki Szpital Kliniczny, Wroclaw, Poland
🇵🇱
Mazowiecki Szpital i Centrum Diagnostyczne Allenort, Warsaw, Poland

and more 8 locations

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CPL500036 compound
Drug: Placebo

First Posted Date: 2019-03-13

Last Posted Date: 2019-10-04

Lead Sponsor: Celon Pharma SA

Target Recruit Count: 56

Registration Number: NCT03873324

Locations: 🇵🇱
BioResearch Group Sp. z o.o., Kajetany, Nadarzyn, Poland

Home Terms & Conditions Privacy Policy